Elderly couple walking in the park

Preserving Brain Health: Advances in Dementia Prevention, Research and Care

Elderly couple at the duckpond, happy

Summary:

Lifestyle interventions, including a healthy diet, regular exercise, cognitive stimulation, stress management, and social engagement, offer promising strategies to reduce the risk of dementia and Alzheimer's disease.

Leqembi, FDA-approved in July 2023, is a breakthrough Alzheimer's treatment that slows cognitive decline by targeting brain amyloid plaques, with other similar drugs like donanemab showing promise in development.

Reframing the dementia narrative from one of despair to one of hope, resilience, and progress is crucial, as it empowers individuals living with dementia, fosters the creation of dementia-friendly communities, and mobilizes resources and expertise to confront the crisis head-on.



Preserving Brain Health

For millions worldwide, the word "dementia" evokes a chilling fear—an unstoppable descent into confusion, isolation and dependence as precious memories fade. Alzheimer's disease, the most common cause of dementia, has become synonymous with this harrowing experience. But what if there was reason for optimism amidst the heartache? What if we could prevent, treat, and one day even cure these devastating conditions, preserving our youthful brains well into old age.

The Promise of Prevention

While the quest for a cure captures headlines, a growing body of research suggests we may already possess some powerful weapons against dementia. Simple lifestyle changes in diet, exercise, sleep, stress management, and cognitive engagement have shown remarkable potential to bolster brain health and resilience.


Consider the groundbreaking Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER). This landmark trial demonstrated that a multi-domain lifestyle intervention could significantly enhance cognitive function in at-risk older adults.(1) By combining a healthy diet, physical exercise, cognitive training, and vascular risk monitoring, participants preserved mental acuity and reduced their dementia risk. The implications are profound—we may be able to substantially delay or prevent cognitive decline through achievable everyday practices.


Other studies reinforce the neuroprotective effects of specific nutrients and dietary patterns. The Mediterranean and MIND diets, rich in vegetables, berries, whole grains, fish, and olive oil, have been associated with slower cognitive aging and reduced Alzheimer's risk.(2) (3) Omega-3 fatty acids, B vitamins, and polyphenols found in foods like green tea and cocoa also show promise in supporting brain function.(4) (5)


While no single superfood can guarantee a lifetime of pristine cognition, a wholesome, plant-forward eating pattern appears to be one of our best defenses. Combined with regular physical activity, quality sleep, social engagement and mentally stimulating pursuits, we have a potent toolkit to promote brain health as we age.

Actionable Steps to Reduce Dementia Risk

Cistanche Plant Photo

So what can we do today to stack the odds in our favor? Here are some evidence-based strategies to incorporate into your daily routine:

  1. Eat a brain-healthy diet: Prioritize colorful fruits and vegetables, whole grains, lean proteins (especially fish), and healthy fats like olive oil and nuts. Limit processed foods, added sugars, and excessive saturated fats.(6)

  2. Stay physically active: Engage in regular exercise, aiming for at least 150 minutes of moderate-intensity activity (like brisk walking) per week. Resistance training and balance exercises are also important for maintaining physical function and preventing falls.(7)

  3. Challenge your brain: Pursue mentally stimulating activities like learning a new language, playing musical instruments, solving puzzles, or engaging in social activities. Continuing education and lifelong learning may help build cognitive reserve.(8)

  4. Prioritize sleep: Aim for 7-9 hours of quality sleep per night. Establish a consistent sleep schedule, create a relaxing bedtime routine, and optimize your sleep environment for comfort and minimal disturbances.(9)

  5. Manage stress: Practice stress-reduction techniques like deep breathing, meditation, yoga, or engaging in enjoyable hobbies. Seek support from friends, family, or mental health professionals when needed.(10)

  6. Stay socially connected: Cultivate and maintain meaningful social relationships. Participate in community activities, volunteer, or join clubs or groups aligned with your interests. Social engagement is associated with a reduced risk of cognitive decline.(11)

  7. Manage cardiovascular risk factors: Work with your healthcare provider to control blood pressure, cholesterol, and blood sugar levels. If you smoke, seek support to quit. What's good for the heart is generally good for the brain.(12)

By incorporating these lifestyle strategies into our daily routines, we empower ourselves to take proactive steps towards better brain health, keeping our brains youthful and resilient. Small, consistent changes can yield significant benefits over time, giving us the best chance to delay or prevent the onset of dementia.

Recent Medical Breakthroughs

An image showing microglia (brain immune cells) activated by and engulfing an amyloid plaque coated with antibodies.
Leqembi's Role in Alzheimer's: Promoting Amyloid Clearance through Microglial Activation

In July 2023, the FDA granted approval to Leqembi (lecanemab), marking it as a groundbreaking treatment designed to address the underlying pathology of Alzheimer’s by targeting amyloid plaques in the brain.(13) While not a cure, Leqembi represents a significant milestone in disease-modifying therapy. Several other anti-amyloid antibodies, including donanemab, have also shown promising results in clinical trials and are advancing through the regulatory pipeline.(14)

Clinical trials have demonstrated that Leqembi can slow cognitive decline in individuals with early-stage Alzheimer's.


Beyond Leqembi, novel therapeutic approaches are emerging. Tau-targeting antibodies aim to prevent the spread of neurofibrillary tangles, another hallmark of Alzheimer's pathology.(15) Inflammation is increasingly recognized as a key player in neurodegeneration, and several anti-inflammatory agents are being investigated for their potential to slow disease progression.(16) Gene therapies, such as CRISPR-based approaches, offer the tantalizing possibility of correcting underlying genetic mutations that contribute to familial Alzheimer's cases.(17)


Advances in early detection are also transforming the landscape of Alzheimer's diagnosis and treatment. Blood-based biomarkers, such as measures of amyloid, tau, and neurofilament light chain, show promise as non-invasive screening tools for identifying individuals at high risk of developing Alzheimer's.(18) Sophisticated brain imaging techniques, like PET scans using novel tracers, can detect pathological changes years before symptoms appear, opening a critical window for early intervention.(19)


While we eagerly await the next breakthroughs, it's important to temper our expectations and recognize that progress is often incremental. Each new discovery builds upon the last, bringing us one step closer to more effective therapies and, ultimately, a cure. In the meantime, we must not neglect the power of prevention and the importance of supporting those currently living with dementia.

Outside the scope of pharmacology, a revolution in dementia care is underway. Person-centered approaches prioritize the unique needs, preferences, and life stories of individuals living with dementia. Innovative therapies like music, art, and reminiscence activities are being used to promote engagement, purpose, and emotional connection. Assistive technologies, from simplified smartphones to GPS tracking devices, are empowering people with dementia to maintain independence and safety.


Support for caregivers is also expanding, with online resources, respite services, and counseling programs acknowledging the profound physical and emotional toll of dementia care. By caring for caregivers, we create a more compassionate and sustainable ecosystem of support.

Rewriting The Dementia Narrative

Multi Generation Family having dinner.

The most transformative shift lies in how we perceive and discuss dementia. For too long, the prevailing narrative has been one of despair, but a growing chorus of voices, led by individuals living with dementia, is challenging these stereotypes.


Advocates like Peter Berry, diagnosed with Alzheimer's at age 51, are redefining what it means to live with the condition, sharing a message of hope and resilience. Grassroots movements are fostering dementia-friendly communities, where people with cognitive impairment are valued, supported, and included. Landmark legislation is mobilizing resources to confront the crisis, but more comprehensive action is needed.  


As we look to the future, let us envision a world where dementia is preventable and perhaps one day, curable. A world where those living with cognitive change are embraced, not marginalized. A world where the fear of losing one's mind is replaced by the confidence that our youthful brains can be preserved, and our best years may still lie ahead.



Author: Fabian Ulrich

In 2024, Fabian co-founded Cognix with a singular mission: to bridge the gap between cognitive science and real-world performance. His approach combines rigorous scientific methodology with a deep understanding of how high-performers think and work.


Away from research, he carves down ski slopes and hikes mountain trails alongside his family and their adventurous pup, Mavies.



Key Research Citations:

  1. Ngandu, T., Lehtisalo, J., Solomon, A., Levälahti, E., Ahtiluoto, S., Antikainen, R., ... & Kivipelto, M. (2015). A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. The Lancet, 385(9984), 2255-2263. 

  2. Scarmeas, N., Anastasiou, C. A., & Yannakoulia, M. (2018). Nutrition and prevention of cognitive impairment. The Lancet Neurology, 17(11), 1006-1015. 

  3. Morris, M. C., Tangney, C. C., Wang, Y., Sacks, F. M., Barnes, L. L., Bennett, D. A., & Aggarwal, N. T. (2015). MIND diet slows cognitive decline with aging. Alzheimer's & dementia, 11(9), 1015-1022. 

  4. Gomez-Pinilla, F. (2008). Brain foods: the effects of nutrients on brain function. Nature reviews neuroscience, 9(7), 568-578. 

  5. Calil, S. R., Brucki, S. M., Nitrini, R., & Yassuda, M. S. (2018). Adherence to the Mediterranean and MIND diets is associated with better cognition in healthy seniors but not in MCI or AD. Clinical Nutrition ESPEN, 28, 201-207. 

  6. Van den Brink, A. C., Brouwer-Brolsma, E. M., Berendsen, A. A., & van de Rest, O. (2019). The Mediterranean, Dietary Approaches to Stop Hypertension (DASH), and Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) diets are associated with less cognitive decline and a lower risk of Alzheimer's disease—a review. Advances in nutrition, 10(6), 1040-1065. 

  7. Livingston, G., Huntley, J., Sommerlad, A., Ames, D., Ballard, C., Banerjee, S., ... & Mukadam, N. (2020). Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. The Lancet, 396(10248), 413-446. 

  8. Yates, L. A., Ziser, S., Spector, A., & Orrell, M. (2016). Cognitive leisure activities and future risk of cognitive impairment and dementia: systematic review and meta-analysis. International psychogeriatrics, 28(11), 1791-1806. 

  9. Spira, A. P., Chen-Edinboro, L. P., Wu, M. N., & Yaffe, K. (2014). Impact of sleep on the risk of cognitive decline and dementia. Current opinion in psychiatry, 27(6), 478. 

  10. Marchant, N. L., & Howard, R. J. (2015). Cognitive debt and Alzheimer's disease. Journal of Alzheimer's Disease, 44(3), 755-770. 

  11. Kuiper, J. S., Zuidersma, M., Oude Voshaar, R. C., Zuidema, S. U., van den Heuvel, E. R., Stolk, R. P., & Smidt, N. (2015). Social relationships and risk of dementia: A systematic review and meta-analysis of longitudinal cohort studies. Ageing research reviews, 22, 39-57. 

  12. Santos, C. Y., Snyder, P. J., Wu, W. C., Zhang, M., Echeverria, A., & Alber, J. (2017). Pathophysiologic relationship between Alzheimer's disease, cerebrovascular disease, and cardiovascular risk: a review and synthesis. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, 7, 69-87. 

  13. Dhillon, S. (2021). Aducanumab: First Approval. Drugs, 81(12), 1437-1443. 

  14. Tolar, M., Abushakra, S., & Sabbagh, M. (2020). The path forward in Alzheimer's disease therapeutics: Reevaluating the amyloid cascade hypothesis. Alzheimer's & Dementia, 16(11), 1553-1560. 

  15. Panza, F., Lozupone, M., Seripa, D., & Imbimbo, B. P. (2019). Amyloid-β immunotherapy for Alzheimer's disease: Is it now a long shot? Annals of neurology, 85(3), 303-315. 

  16. Heneka, M. T., Carson, M. J., El Khoury, J., Landreth, G. E., Brosseron, F., Feinstein, D. L., ... & Kummer, M. P. (2015). Neuroinflammation in Alzheimer's disease. The Lancet Neurology, 14(4), 388-405. 

  17. Giau, V. V., Lee, H., Shim, K. H., Bagyinszky, E., & An, S. S. A. (2018). Genome-editing applications of CRISPR–Cas9 to promote in vitro studies of Alzheimer's disease. Clinical interventions in aging, 13, 221. 

  18. Molinuevo, J. L., Ayton, S., Batrla, R., Bednar, M. M., Bittner, T., Cummings, J., ... & Blennow, K. (2018). Current state of Alzheimer's fluid biomarkers. Acta neuropathologica, 136(6), 821-853. 

  19. Young, P. N., Estarellas, M., Coomans, E., Srikrishna, M., Beaumont, H., Maass, A., ... & Fox, N. C. (2020). Imaging biomarkers in neurodegeneration: current and future practices. Alzheimer's research & therapy, 12(1), 1-17. 

  20. Dhillon, S. (2021). Aducanumab: First Approval. Drugs, 81(12), 1437-1443. 

  21. Cummings, J., Lee, G., Ritter, A., Sabbagh, M., & Zhong, K. (2020). Alzheimer's disease drug development pipeline: 2020. Alzheimer's & Dementia: Translational Research & Clinical Interventions, 6(1), e12050. 

  22. Nakamura, A., Kaneko, N., Villemagne, V. L., Kato, T., Doecke, J., Doré, V., ... & Yanagisawa, K. (2018). High performance plasma amyloid-β biomarkers for Alzheimer's disease. Nature, 554(7691), 249-254.  

Back to blog

Leave a comment

Please note, comments need to be approved before they are published.